Tag: Spdr S&P Biotech Etf

Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’

Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Many bought this stock to play the GLP-1 boom, but it has bigger opportunities to boost its share price

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Novo Nordisk shares slide after guidance disappoints investors

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

The market for psychedelic drugs to treat mental health conditions gets a big buy signal